You can write off another experimental obesity drug. In a tersely worded statement, Merck announced that it is
Merck has pulled the plug on its obesity drug taranabant, saying that efficacy and adverse events both increased at higher doses.
An influential pharma analyst downgraded Merck shares, saying they've hit their price ceiling. Why? The reasons can be summed up in four drugs: Singulair, Gardasil, taranabant, and Vytorin. Sanford
Americans hoping to trim the fat by popping a pill have been wondering when and if the weight loss drug Acomplia will hit the U.S.
Fortune writer John Simons is taking Merck to task for two development programs he finds particularly risky. "The riskiest of Merck's current projects is
As America's obesity epidemic continues, biotech and pharmaceutical companies are racing to create a pill that delivers significant weight loss without the unpleasant side effect of current obesity
At a meeting with investors yesterday, Merck highlighted several of its late-stage pipeline hopes. One of the most-watched drug candidates in Merck pipeline, of course, is anacetrapib--a drug in the